The potential of cystatin C as a predictive biomarker in pulmonary hypertension

BMC Pulmonary Medicine

Table 3 Multivariate Cox regression models of cystatin C and prognosis

Variables	HR	95% CI	P-value
Model 1
Cystatin C	2.184	1.200–3.975	0.011
Age	0.998	0.980–1.015	0.998
Female	1.294	0.799–2.095	0.295
PH subtype	0.797	0.567–1.121	0.192
Combined target therapy	0.462	0.245–0.872	0.017
Model 2
Cystatin C	2.212	1.184–4.131	0.013
RAP	1.070	1.015–1.129	0.012
S_vO₂	0.962	0.928–0.998	0.037
CI	0.847	0.606–1.184	0.332
Model 3
Cystatin C	2.266	1.210–4.244	0.011
WHO-FC: III or IV/I or II	2.041	1.230–3.388	0.006
NT-proBNP	1.000	1.000–1.000	0.420
Model 4
Cystatin C	2.080	1.085–3.985	0.027
Swedish/COMPERA	2.483	1.646–3.744	< 0.001

Four models were constructed to adjust clinical features, hemodynamic parameters, non-invasive parameters and Swedish/COMPERA risk stratification, respectively
CI Cardiac index, COMPERA Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension, NT-proBNP N-terminal pro-brain natriuretic peptide, PH Pulmonary hypertension, RAP Right atrium pressure, S_vO₂ Mixed venous oxygen saturation, WHO-FC World Health Organization functional class

ISSN: 1471-2466